Included trials | Eligibility criteria | Study designs | Interventions | Sample and characteristics (male/female; age ;Duration) | Outcome index | Intergroup differences | ||
---|---|---|---|---|---|---|---|---|
 |  |  | Trial | control | Trial | control |  |  |
WU 2005[31] | GCTNPCM in I993 | RCT (method unreported) and controlled nonblind parallel study | Modified suanzaorentang 1dose/d for 2 week | alprazolam 0.4-1.2 mg/p.t qn for 2 week | 70 (M:30, F:40) Mean age: Mean age: 48y Disease duration: 6 m-9y | 70 (M:32, F:38) Mean age: 47y Disease duration: 6 m-9y | 1. Clinical effect | 1. p < 0.05 |
2. adverse effect | 2.P < 0.01 | |||||||
Yu 2005[32] | CCMD-III | RCT (Psychological test Numbers) and controlled nonblind parallel study | Modified Suanzaorentang 1dose/d+Lorazepam o.5 mg qn for 4 weeks | Lorazepam o.5 mg qn for 4 weeks | 48 (M:22, F:26) Mean age: Mean age: 32.6±8.9y Disease duration: 1.5 m-10y | 45 (M:23, F:22) Mean age: Mean age: 30.6±8.4y Disease duration: 1 m-12y | 1. SDRS | 1. p < 0.05 |
2. HAMA | 2. p < 0.05 | |||||||
3. CGI | 3.P > 0.05 | |||||||
Tan 2006[35] | CCMD-III | RCT (method unreported) and controlled nonblind parallel study | Suanzaorentang 1dose/d (150 ml) + Oxazepam 60 mg/d For 30d | Oxazepam 60 mg/d For 30d | N.R N.R N.R | N.R N.R N.R | Clinical effect | p < 0.05 |
Yu 2006[36] | CCMD-III | RCT (method unreported) and controlled nonblind parallel study | Baihesuan Zaorentang 1dose/d (300 ml) for 3 week | estazolam 2 mg/p.t qn For 3 weeks | 63 (M:34, F:29) 63(M:34, F:29) Mean age: 31.2y Mean disease duration: 2.3y | 57 (M:30, F:27) 63(M:34, F:29) Mean age: 31.3y Mean disease duration: 2.4y | 1. Clinical effect | 1.p < 0.05 |
2.adverse effect | 2.p < 0.01 | |||||||
Wu 2008[42] | CCMD-III+GCTNPCM in I993 | RCT (method unreported) and controlled single-blind 3-group design study | Modified Suanzaorentang 1dose/d For 14d | alprazolam 0.2-0.6 mg/pt qn For 14d | 70 (M:30, F:40) Mean age: Mean age: 48y Disease duration: 6 m-9y | 70 (M:32, F:38) Mean age: Mean age: 47y Disease duration: 6 m-9y | 1. Clinical effect | 1. P < 0.01 |
2. PSQI | 2. P < 0.01 | |||||||
3. adverse effect | 3.P < 0.01 | |||||||
Modified Suanzaorentang 1dose/d + alprazolam 0.2-0.6 mg/pt qn For 14d | alprazolam 0.2-0.6 mg/pt qn For 14d | 260 (M:98, F:162) Mean age: Mean age: 48.5y Disease duration: 6 m-10y | 70 (M:32, F:38) Mean age: Mean age: 47y Disease duration: 6 m-9y | 1. Clinical effect | 1. P < 0.01 | |||
2. PSQI | 2. P < 0.01 | |||||||
3. adverse effect | 3. P < 0.01 | |||||||
She 2009[37] | CCMD-III | RCT (random number table) a And controlled nonblind parallel study | Modified Suanzaorentang 1dose/d (300 ml) Divide two time for 4 week | diazepam 5 mg/pt qn For 4 weeks | 60 (-,-) Mean age: 36.±8.53y Mean disease duration: 3.22±3.37y | 59 (-,-) Mean age: 35.32±9.13y Mean disease duration: 3.51±3.67y | 1. Clinical effect | 1. P < 0.01 |
2. PSQ I | 2. P < 0.05 | |||||||
Yuan 2009[38] | CCMD-2-R | RCT (random number table) and controlled nonblind parallel study | Modified Suanzaorentang 1dose/d Divide two time for 15d | estazolam 2 mg/pt qn For 15d | 69 (M:27, F:42) Mean age: Mean age: 37y Disease duration: | 65 (M:23, F:42) Mean age: Mean age: 37y Disease duration: | 1. Clinical effect | 1. P < 0.05 |
2. timeliness of drug | 2. P < 0.05 | |||||||
Luo 2009[34] | CCMD-III | RCT (method unreported) and controlled nonblind parallel study | Suanzaorentang 1dose/d (250 ml) Divide two time For 15d | diazepam 2.5-5 mg/pt qn For 15d | 30 (M:12, F:18) Mean age: Mean age: 60y Mean disease duration: 15y | 30 (M:13, F:17) Mean age: 62y Mean disease duration: 16y | Clinical effect | P < 0.05 |
Zou 2011[40] | GCTNPCM in 1993 | RCT (method unreported) and controlled nonblind parallel study | Suanzaorentang 1dose/d + estazolam 2 mg/pt qn For 4 weeks | estazolam 2 mg/pt qn For 4 weeks | 25 (M:12, F:13) Mean age: Mean age: 48.82±4.32y Disease duration: 2 m-13 m | 25 (M:13, F:12) Mean age: Mean age: 47.74±3.98y Disease duration: 1 m-13 m | Clinical effect | P < 0.05 |
Cong 2011[41] | GCTNPCM in I993 | RCT (method unreported) and controlled nonblind parallel study | Modified Suanzaorentang 1dose/d Divide two time for 4 week | diazepam 2.5-5 mg/pt qn For 4 weeks | 59 (M:18, F:41) Mean age: Mean age: 40y Mean disease duration: 3y | 59 (M:17, F:42) Mean age: 39y Mean disease duration: 2.6y | Clinical effect | p > 0.05 |
Feng 2011[39] | CCMD-III | RCT (method unreported) and controlled nonblind parallel study | Modified Suanzaorentang 1dose/d (150 ml) qn for 2 week | estazolam 2 mg/pt qn For 2 weeks | 78 (M:31, F:47) Mean age: Mean age: 39.53y Mean disease duration: 5.3mo | 69 (M:25, F:44) Mean age: 38.89y Mean disease duration: 5.1mo | 1. Clinical effect | 1. p > 0.05 |
2. Spiegel sleep questionnaire | 2. P < 0.05 | |||||||
Liu 2012[33] | CCMD-III | RCT (method unreported) and controlled nonblind parallel study | Modified Suanzaorentang 1dose/d for 14d | diazepam 5 mg/pt qn For 14d | 50 (M:25, F25) Mean age: Mean age: 48.5±20.3y Disease duration: 1 m-51 m | 25 (M:24, F:26) Mean age: Mean age: 46.3±17.8y Disease duration: 2 m-42 m | 1. Clinical effect | 1. p > 0.05 |